Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
about
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansApixaban and oral implicationsGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentThe Reversal of Direct Oral Anticoagulants in Animal Models.The role of prothrombin complex concentrates in reversal of target specific anticoagulants.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human bloodEx vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.New oral anticoagulants for atrial fibrillation: are they worth the risk?Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complicationsIntracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.Emergency reversal of anticoagulation: novel agents.Management of hemorrhage with the target-specific oral anticoagulants.Monitoring and reversal strategies for new oral anticoagulants.Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.Who, when, and how to reverse non-vitamin K oral anticoagulants.The epidemic of pre-injury oral antiplatelet and anticoagulant use.Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.Practical management of patients on apixaban: a consensus guide.Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.New oral anticoagulants: an emergency department overview.Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate.Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.Multimodal assessment of non-specific hemostatic agents for apixaban reversal
P2860
Q26746917-7C587455-5DC5-4334-8F8F-69E2C100E863Q26780328-8E4E8B26-03E6-4255-B80E-F0061126B324Q28076077-457469F0-C3C6-41A0-AB2C-BB0E4445AECCQ30491580-E7A70FFE-42E1-422F-955B-9D224F014BE7Q33582537-34B964BA-67AC-4A24-A764-2EED89C57F74Q34469002-A474FF55-65BD-4C3E-9BE0-A5B9735766B8Q34482427-4763AD76-4788-474A-B72C-0C77B2D13D8AQ34667503-71E72A82-E616-4E12-9BEC-01673F8255D6Q35746798-6C415BA5-3775-4AE8-A9D2-AED4DACC858FQ36458797-EA07840E-372C-4E6A-8EF8-AF456FA519E6Q37297475-79D9E39E-D693-4295-9326-945B6A066254Q37388007-FAAABCA8-A965-4B73-99A8-B06D541521B7Q37641289-A880DEC7-EB47-4544-8C5E-455F8D88CFDBQ37701146-0E6AD9A6-CB95-4F09-BEF7-01A2431DF146Q38117418-AFB11BEF-23C8-49EE-838B-49B7A6B62AF9Q38197124-5149ECC7-086C-48EC-9AF2-82B073BAEA63Q38221642-01AFE8A7-B56B-410F-AB4E-140E34C03339Q38223609-BDBEB5FC-3364-415A-A662-4ED429EF5005Q38254250-60616CF4-C199-4760-8C47-7DC055AD6CBFQ38272325-AC8620D7-FA13-4034-B628-57456D25CB72Q38602484-2E448399-9098-4D83-A4E5-84023E5653ABQ38620930-D6C3C6BD-92EC-44D6-85D2-2EE90C9EBAA9Q38655960-16F5B2E6-BC19-4DA3-8A35-E98C7433971DQ38915687-7801C6F6-0E94-4928-A9E2-ECE6947F46B7Q40081589-19DF2D14-70F9-4592-ACA1-8D7B1D17675AQ40454557-05957FD9-9E22-4F23-A29C-683185AAEFEEQ41485925-DF799895-8E6B-494B-956E-AD0A40601968Q41890211-0AB44349-D456-4AEC-B45C-C1ECF4A31BDDQ48599279-DA4386C4-14C8-4699-82E4-2FB92156F438Q52625566-27CBBAA7-4FBE-4528-BAF9-E39FA0CB1D05Q54610809-611BBD9F-EF1D-466A-8B7D-EC3F384466F8Q55098543-EADA4402-CE51-4CD8-B2FE-61D79C7FA03BQ55272081-D2D4C283-0524-463A-8B4F-9FEA462E8249Q59268547-A481F332-14D2-44ED-A93C-8CF20B84EAE8
P2860
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@en
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@nl
type
label
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@en
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@nl
prefLabel
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@en
Evaluation of recombinant acti ...... el of bleeding and thrombosis.
@nl
P2093
P50
P1476
Evaluation of recombinant acti ...... del of bleeding and thrombosis
@en
P2093
Anne Godier
Anne-Marie Fischer
Charles-Marc Samama
P304
P356
10.1016/J.IJCARD.2013.07.152
P407
P577
2013-08-06T00:00:00Z